Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma

References

• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964; 1: 702–703.
   PubMed Web of Science ®Google Scholar
• Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007; 38: 1293–1304.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13: 577–585.
   PubMed Web of Science ®Google Scholar
• Zhang T, Fu Q, Gao D, et al. EBV associated lymphomas in 2008 WHO classification. Pathol Res Pract 2014; 210: 69–73.
   PubMed Web of Science ®Google Scholar
• Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br J Haematol 2013; 162: 573–586.
   PubMed Web of Science ®Google Scholar
• Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol 2013; 23: 457–467.
   PubMed Web of Science ®Google Scholar
• Gibson TM, Engels EA, Clarke CA, et al. Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol 2014; 89: 714–720.
   PubMed Web of Science ®Google Scholar
• Massini G, Siemer D, Hohaus S. EBV in Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2009 Nov 24;1.
   Google Scholar
• Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV + Hodgkin lymphoma. Blood 2007; 110: 3310–3315.
   PubMed Web of Science ®Google Scholar
• Ok CY, Papathomas TG, Medeiros LJ, et al. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013; 122: 328–340.
   PubMed Web of Science ®Google Scholar
• Oyama T, Ichimura K, Suzuki R, et al. Senile EBV + B cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003; 27: 16–26.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein–Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972–978.
   PubMed Web of Science ®Google Scholar
• Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007; 13: 5124–5132.
   PubMed Web of Science ®Google Scholar
• Gibson SE, Hsi ED. Espstein–Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009; 40 653–661.
   PubMed Web of Science ®Google Scholar
• Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 352–357.
   PubMed Web of Science ®Google Scholar
• Hofscheier APA, Bonzheim I, Adam P, et al. Geographic variation in the prevalence of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011; 24: 1046–1054.
   PubMed Web of Science ®Google Scholar
• Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol 2011; 86: 663–667.
   PubMed Web of Science ®Google Scholar
• Chang ST, Lu YH, Lu CL, et al. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol 2014; 67: 326–332.
   PubMed Web of Science ®Google Scholar
• Ok CY, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 2014; 20: 2338–2349.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus [EBV] DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243–249.
   PubMed Web of Science ®Google Scholar
• Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus [EBV] genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int J Cancer 1999; 84: 442–448.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus [EBV] DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin Cancer Res 2006; 12: 460–464.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus [EBV] DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res 2011; 17: 2885–2892.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 2013; 121: 3547–3553.
   PubMed Web of Science ®Google Scholar
• Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92: 1011–1019.
   PubMed Web of Science ®Google Scholar
• Jones K, Nourse JP, Keane C, et al. Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol 2012; 87: 258–265.
   PubMed Web of Science ®Google Scholar
• Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011; 117: 4726–4735.
   PubMed Web of Science ®Google Scholar
• Cohen M, Narbaitz M, Metrebian F, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients. Int J Cancer 2014; 135: 2816–2824.
   PubMed Web of Science ®Google Scholar
• Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35–42.
   PubMed Web of Science ®Google Scholar
• Marques H, Catarino R, Domingues N, et al. Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin’s lymphoma is not associated with prognosis. Oncol Lett 2012; 4: 1285–1289.
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Wagner WM, Walter S, et al. An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus [EBV] epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 2003; 124: 477–485.
   PubMed Web of Science ®Google Scholar
• Levin LI, Chang ET, Ambinder RF, et al. Atypical pre diagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood 2012; 120: 3750–3755.
   PubMed Web of Science ®Google Scholar
• Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014; 99: 489–496.
   PubMed Web of Science ®Google Scholar
• Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545–2553.
   PubMed Web of Science ®Google Scholar
• Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 2010; 10: 514–526.
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29–37.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492–499.
   PubMed Web of Science ®Google Scholar
• Rossille D, Gressier M, Damotte D, et al; for the Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28: 2367–2375.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119: 4129–4132.
   PubMed Web of Science ®Google Scholar